Announcements Trials
Browse Landscape

Status

Recruiting 494Completed 195Active not recruiting 189Not yet recruiting 113Enrolling by invitation 33Terminated 28Withdrawn 12Suspended 8Available 2

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Carcinoma, Non-Small-Cell Lung 4Sarcoma 3Pancreatic Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasms 2Melanoma 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurofibrosarcoma 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neuroblastoma 1Myelodysplastic Syndromes 1Meningioma 1Mastocytosis, Systemic 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Mast-Cell 1Leukemia 1Insulinoma 1Hypoglycemia 1Hyperinsulinism 1

Interventions

balstilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Available × Neoplasms × 90 days × Clear all
NCT05572970 2026-05-06

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Agenus Inc.

Available
Tumor-Agnostic

Neoplasms

NCT06761976 2026-05-05

Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

Bayer

Available
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡